Modeling HIV disease progression and transmission at population-level: The potential impact of modifying disease progression in HIV treatment programs

SOURCE: Epidemics
OUTPUT TYPE: Journal Article
PUBLICATION YEAR: 2018
TITLE AUTHOR(S): J.M.Ross, R.Ying, C.L.Celum, J.M.Baeten, K.K.Thomas, P.M.Murnane, H.Van Rooyen, J.P.Hughes, R.V.Barnabas
KEYWORDS: HIV/AIDS, HIV/AIDS PREVENTION, HIV/AIDS TREATMENT
Intranet: HSRC Library: shelf number 10300
HANDLE: 20.500.11910/12039

If you would like to obtain a copy of this Research Output, please contact Hanlie Baudin at researchoutputs@hsrc.ac.za.

Abstract

Mathematical models that incorporate HIV disease progression dynamics can estimate the potential impact of strategies that delay HIV disease progression and reduce infectiousness for persons not on antiretroviral therapy (ART). Suppressive treatment of HIV-positive persons co-infected with herpes simplex virus-2 (HSV-2) with valacyclovir, an HSV-2 antiviral, can lower HIV viral load, but the impact of partially-suppressive valacyclovir relative to fully-suppressive ART on population HIV transmission has not been estimated.Even when compared with valacyclovir suppression, a drug that reduces HIV viral load, universal treatment for HIV is the optimal strategy for averting new infections and increasing public health benefit. Universal HIV treatment would most effectively and efficiently reduce the HIV burden.